Extracellular vesicle protein and nucleic acid analysis
The modified workflow for detecting protein and nucleic acid targets in EVs addresses the limitations of existing methods by using a cleavable linker and signal amplification, enabling simultaneous detection and enhancing the analysis of biomarker signatures in liquid biopsies.
Patent Information
- Application Number
- PCT/US2024/028489
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-16
- Filing Date
- 2024-05-09
- Publication Date
- 2024-11-21
AI Technical Summary
Current methods are inadequate for simultaneously detecting protein and nucleic acid targets in extracellular vesicles using flow cytometry, as existing techniques face challenges with permeabilization that can lead to loss of cargo and elimination of smaller vesicles, limiting the analysis of biomarker signatures in liquid biopsies.
A modified workflow involving capturing EVs on a solid surface, labeling with detectably labeled antibodies, contacting with fixation and permeabilization reagents, and using a signal generating system with nucleic acid detection reagents, allowing for the detection of both protein and nucleic acid targets in a single assay, utilizing a cleavable linker for reversible binding and signal amplification components like branched nucleic acids for enhanced sensitivity.
Enables the simultaneous detection of protein and nucleic acid targets in EVs, conserving sample and time, and allowing for the analysis of disease-specific biomarker signatures, such as cancer-specific miRNA, with improved sensitivity and specificity, suitable for liquid biopsies and therapeutic cargo validation.
Smart Images

Figure US2024028489_21112024_PF_FP_ABST
Abstract
Description
[0001] EXTRACELLULAR VESICLE PROTEIN AND NUCLEIC ACID ANALYSIS
[0002] RELATED APPLICATIONS
[0003] The present application includes subject matter that is related to subject matter disclosed by U.S. provisional application No. 63 / 502,545, filed May 16, 2023, which is incorporated herein by reference.
[0004] FIELD
[0005] This disclosure relates to methods of detecting protein and nucleic acid targets in extracellular vesicles, particularly using flow cytometry methods.
[0006] BACKGROUND
[0007] Extracellular vesicles (EVs) are emerging as promising players in the development of novel therapeutic and minimally invasive diagnostic tools to analyze liquid biopsies from blood, urine, or saliva. EVs are highly heterogeneous, and their cargo is believed to command their pathophysiological effect. In addition, EV protein and RNA cargo bears potential to function as unique biomarker(s) for oncology, neurological diseases, autoimmune disorders, etc. For example, certain microRNA cargo signatures have been associated with specific types of cancer, which could be utilized in detecting early disease onset, progression, or monitoring therapeutic efficacy. Consequently, characterizing EV subpopulations is important in understanding their biological function, and also in defining and detecting disease related biomarker signatures.
[0008] In addition, progress in engineering EVs holds promise for novel therapeutic approaches in which EVs transfer deliberate cargo to recipient cells. Engineered EVs could be applied in vaccine or drug delivery and enable applications in regenerative medicine and gene therapy. In this case, a simple approach to determine successful bioengineering of the cargo of interest would be desirable. In both diagnostic and therapeutic applications, defining protein and RNA cargo simultaneously in one sample with an easily accessible technology such as flow cytometry, would enable researchers to conserve sample and time.
[0009] SUMMARY
[0010] Provided here are methods of detecting one or more protein and one or more nucleic acid targets in EVs, for example, simultaneously detecting protein and nucleic acid targets in EVs in a single workflow or assay. In some aspects, the methods include detection the one or more protein and nucleic acid targets in single EVs.
[0011] In some aspects, the methods include capturing EVs from a sample on a solid surface or bead to produce captured EVs, labeling the captured EVs with one or more detectably labeled antibodies, contacting the captured EVs with a fixation reagent, contacting the captured EVs with a permeabilization reagent, contacting the captured EVs with one or more nucleic acid detection reagents comprising a signal generating system, and detecting the one or more labeled antibodies and detecting a signal generated by the signal generating system, thereby detecting the one or more protein and one or more nucleic acid targets in the EVs. In other aspects, the methods include labeling EVs in a sample with one or more detectably labeled antibodies, capturing the EVs on a solid surface or bead to produce captured EVs, contacting the captured EVs with a fixation reagent, contacting the captured EVs with a permeabilization reagent, contacting the captured EVs with one or more nucleic acid detection reagents comprising a signal generating system, and detecting the one or more labeled antibodies and detecting a signal generated by the signal generating system, thereby detecting one or more protein and one or more nucleic acid targets in the EVs.
[0012] In other aspects, the methods include capturing EVs in the sample on a first solid surface or bead to produce captured EVs; releasing the captured EVs from the solid surface or bead to produce released EVs; labeling the released EVs with one or more detectably labeled antibodies; contacting the released EVs with a fixation reagent; contacting the released EVs with a permeabilization reagent; contacting the released EVs with one or more nucleic acid detection reagents comprising a signal generating system to provide treated EVs; capturing the treated EVs on a second solid surface or bead to produce captured, treated EVs; and detecting the one or more labeled antibodies and detecting a signal generated by the signal generating system, thereby detecting the one or more protein and one or more nucleic acid targets in the EVs.
[0013] In some aspects, the captured EVs are reversibly bound to the solid surface or bead, for example by a cleavable linker or a nano DNA structure. In particular examples, the cleavable linker is a DNA linker (for example, a DNA linker cleavable by DNase I) or an enzyme cleavage site. Other types of linkers include chemi cally- cleavable linkers. In some examples, the solid surface or bead includes magnetic beads. In some aspects, the methods further include releasing the reversibly bound captured EVs from the solid surface or bead prior to detecting the one or more labeled antibodies and detecting a signal generated by the signal generating system.
[0014] In some aspects, the signal generating system includes a target-specific nucleic acid probe and a signal amplification component. In some examples, the signal amplification component comprises a branched nucleic acid (e.g., a pre-amplifier), an amplifier, and a detectably labeled probe. In further examples, the detectably labeled probe includes one or more fluorophores. In particular aspects, detecting the one or more labeled antibodies and detecting the signal generated by the signal generating system utilizes flow cytometry.
[0015] In additional aspects, the methods further include one or more washing steps. In some examples, the one or more washing steps are between contacting the captured EVs with a fixation reagent and contacting the captured EVs with a permeabilization reagent and / or between contacting the captured EVs with a permeabilization reagent and contacting the captured EVs with the one or more nucleic acid detection reagents. In some examples, the washing steps are with a wash buffer including EV-depleted fetal bovine serum.
[0016] In some aspects, the one or more nucleic acid targets are RNA, such as one or more of mRNA, miRNA, long non-coding RNA, and small non-coding RNA. In further aspects, the sample is a biological specimen (for example, a liquid biopsy specimen). In some examples, the sample is from a subject with a disease or disorder, for example, a subject with cancer, a neurological disorder, a cardiovascular disorder, an infectious disease, a metabolic disorder, or an immunological disorder.
[0017] The foregoing and other features of this disclosure will become more apparent from the following detailed description of several aspects which proceeds with reference to the accompanying figures.
[0018] BRIEF DESCRIPTION OF THE DRAWINGS
[0019] FIG. l is a schematic diagram of an exemplary method of detecting protein and RNA in immobilized EVs.
[0020] FIGS. 2A-2G show detection of miR-146a in human PBMC. FIG. 2A shows FSC vs. SSC gating on human PBMC cells. FIG. 2B shows singlet gating on monocytes. FIG. 2C shows miR- 146a signal in CD9 monocytes. FIG. 2D shows singlet gating on lymphocytes. FIG. 2E shows high and low signal of miR- 146a on lymphocytes. FIG. 2F shows miR-146a signal in CD9 lymphocytes. FIG. 2G shows miR-146a signal in myeloid cells (pink) and in lymphocytes (green).
[0021] FIGS. 3A-3D show tetraspanin detection in single EVs. FIG. 3A shows Invitrogen™ Virocheck beads were used to help locate single-EVs. FIG. 3B shows CD9, CD63, and CD81 detection in human plasma-derived single EVs, following magnetic bead purification. CD9 is clearly present, whereas CD63 and CD81 are considerably less. FIG. 3C shows CD9 PE antibody and FIG. 3D shows isotype control titrations were used to determine application-dependent optimal concentrations for CD9 PE. Plasma-derived EVs were stained overnight at 2x, lx, 0.5x and 0.25x (from left to right) of the optimal concentration, then washed and eluted the following morning. No increase in signal was observed at 2x, and a drop in signal was detected at 0.5x and 0.25x.
[0022] FIGS. 4A-4E show mRNA and miRNA detection of immobilized fixed EVs by flow cytometry. FIG. 4A shows FSC / SCC and doublet exclusion of EVs bound to magnetic beads. FIG. 4B shows CD9-PE bound EVs single color control. FIG. 4C shows no-plasma sample controls of mRNA and miRNA probes. FIG. 4D shows single color controls of mRNA and miRNA probe detections in bound EVs. FIG. 4E shows CD9+mRNA or miRNA probe detections of GAPDH (left), RPAL13a (middle) and miR-146a (right) in bound EVs. Higher detection of miR-146a than GAPDH and RPL13a was observed in human-derived plasma EVs.
[0023] DETAILED DESCRIPTION
[0024] The Invitrogen™ PrimeFlow™ RNA assay (available from Thermo Fisher Scientific; Waltham, MA) was originally developed to allow for simultaneous detection of specific RNA and protein targets in cells by flow cytometry. After antibody staining (optional intracellular staining), sequence specific probes are hybridized to miRNA or mRNA sequence of interest. This step is followed by detection of fluorescent branched DNA (bDNA), leading to an amplification of the signal, even at low copy numbers. This assay enables detection of up to four distinct RNA targets at the singlecell level.
[0025] As PrimeFlow™ has been established for cells; however, extracellular vesicles (EVs) are significantly smaller, permeabilization required for shuttling bDNA and probes into the lumen may cause loss of cargo, surface protein, and / or elimination of smaller vesicles. Described herein are methods for detecting both protein and nucleic acid targets in EVs utilizing a modification of the PrimeFlow™ method. miRNA cargo of EVs has been described as having biomarker potential in context with different types of cancer, or infectious diseases. The methods provided herein for EVs can enable analysis of liquid biopsies and biomarker discovery of disease-specific miRNA signatures (such as cancer-specific signatures). This technology allows for the use of one application to look at two different types of biomolecules, with the additional benefit of conserving sample.
[0026] I. Methods of Detecting Protein and RNA in Extracellular Vesicles
[0027] Provided here are methods of detecting one or more protein and one or more nucleic acid targets in EVs, for example, detecting protein and nucleic acid targets in EVs in a single workflow or assay. An exemplary workflow is illustrated in FIG. 1. While the methods are described herein with respect to EVs, these methods could also be used for detecting one or more protein and one or more nucleic acid targets in other types of particles (for example, lipid nanovesicles, such as synthetic lipid nanovesicles, or viral particles).
[0028] In some aspects, the methods include capturing EVs from a sample on a solid surface or bead to produce captured EVs, labeling the captured EVs with one or more detectably labeled antibodies, contacting the captured EVs with a fixation reagent, contacting the captured EVs with a permeabilization reagent, contacting the captured EVs with one or more nucleic acid detection reagents comprising a signal generating system, and detecting the one or more labeled antibodies and detecting a signal generated by the signal generating system, thereby detecting one or more protein and one or more nucleic acid targets in the EVs. In other aspects, the methods include labeling EVs in a sample with one or more detectably labeled antibodies, capturing the EVs on a solid surface or bead to produce captured EVs, contacting the captured EVs with a fixation reagent, contacting the captured EVs with a permeabilization reagent, contacting the captured EVs with one or more nucleic acid detection reagents comprising a signal generating system, and detecting the one or more labeled antibodies and detecting a signal generated by the signal generating system, thereby detecting one or more protein and one or more nucleic acid targets in the EVs. Thus, in aspects of the methods, one or more protein targets may be labeled before or after EV capture. In additional aspects, one or more protein targets may be labeled both before and after EV capture.
[0029] In some aspects, methods are provided for detecting one or more protein and one or more nucleic acid targets in EVs that include multiple capture and release steps. An example of a such a method can include capturing EVs from a sample on a solid surface or bead to produce captured EVs, releasing the captured EV's, labeling the captured EVs with one or more detectably labeled antibodies, contacting the EVs with a fixation reagent, contacting the EVs with a permeabilization reagent, contacting the EVs with one or more nucleic acid detection reagents including a signal generating system, capturing the treated EV's, detecting the one or more labeled antibodies and detecting a signal generated by the signal generating system, thereby detecting one or more protein and one or more nucleic acid targets in the EVs.
[0030] EVs are lipid bound vesicles secreted by cells into the extracellular space. In some aspects of the methods, the EVs are exosomes. Exosomes are a class of cell- derived extracellular vesicles of endosomal origin and can be 30-200 nm (e.g., about 50-100 nm) in diameter. Exosomes are released into the extracellular environment and contain components derived from the original cell, such as, but not limited to, proteins, lipids, RNA (such as mRNA and / or miRNA), and / or DNA. Exosomes have an endosomal origin and are formed through the fusion and exocytosis of multivesicular bodies into the extracellular space. In other examples, the EVs are microvesicles or apoptotic bodies. In some aspects of the methods, the EVs are engineered EVs.
[0031] In some aspects, the captured EVs are reversibly bound to the solid surface or bead, for example by a cleavable linker or a nano DNA structure. In some embodiments, the cleavable linker is a chemically-cleavable linker. In particular examples, the cleavable linker is a DNA linker (for example, a DNA linker cleavable by DNase I) or an enzyme cleavage site. In some examples, the solid surface or bead is polymer-based. In some examples, the solid surface or bead comprises magnetic beads.
[0032] In some aspects, the disclosed methods include detecting the one or more protein and nucleic acid targets at the single EV level. Thus, in some examples, the methods further include releasing the reversibly bound captured EVs from the solid surface or bead prior to detecting the one or more labeled antibodies and detecting a signal generated by the signal generating system. In some examples, prior to the detecting, the captured EVs are contacted with a reagent or incubated under conditions that release the captured EVs from the solid surface or bead. In one example, the captured EVs are reversibly bound to the solid surface or bead by a cleavable linker and the captured EVs are contacted with a reagent that can cleave the linker. In a specific example, the cleavable linker is a DNA linker and the EVs are released from the solid surface or bead by incubating with DNase I, which cleaves the DNA linker. In another specific example, the cleavable linker includes an enzyme cleavage site and the EVs are released from the solid surface or bead by incubating with an enzyme capable of cleaving the enzyme cleavage site. In other examples, the reversible binding include a DNA nanostructure (also referred to herein as a nano DNA structure). In some examples, This immobilization by the DNA nanostructure may be released in response to a specific stimulus, including but not limited to light of a particular wavelength, photoisomerization, photocleavage, photothermal response, pH-responsiveness, response to ATP, enzyme based cleavage, or oligonucleotide mediated release response. Exemplary DNA nanostructures are known to one of ordinary skill in the art, for example, as described in Wang et al. (Smart Materials in Medicine 3:66-84, 2022) and Chandrasekaran (Nature Reviews Chemistry 5:225-239, 2021).
[0033] In aspects, the methods include contacting the captured EVs with a permeabilization reagent. In some examples, the permeabilization reagent includes a detergent or surfactant, for example, a non-ionic detergent or surfactant. Exemplary detergents include Triton™ X detergents (such as Triton™ X-100), Tween® detergents (such as Tween® 20), Nonidet® P-40, Brij® detergents (such as Brij® 35), octyl 0- glucoside, tyloxapol, Span® 80, decaethylene glycol monododecyl ether, IGEPAL® CA-720, nonaethylene glycol monododecyl ether, n-dodecyl 0-D-glucopyranoside, and saponin. In particular aspects, the permeabilization reagent includes an amount of the detergent or surfactant that permeabilizes the captured EVs, while maintaining structural integrity of the EVs and conserving EV cargo.
[0034] In aspects, the methods include contacting the captured EVs with a fixation reagent. Exemplary fixatives included in the fixation reagent include glyoxal, formaldehyde, paraformaldehyde, methanol, and / or ethanol. In particular aspects, the fixation reagent includes an amount of fixative that crosslinks macromolecules (such as proteins) for example to retain molecules of interest prior to permeabilization of the EVs.
[0035] In some aspects, the methods include contacting the EVs with one or more detectably labeled antibodies. The one or more detectably labeled antibodies are capable of specifically binding to a protein target of interest that is present or may be present in the EVs. In some examples, the one or more antibodies are labeled with a fluorophore. Exemplary fluorophores include phycoerythrin (such as R-PE), allophycocyanin (APC), fluorescein isothiocyanate (FITC), and various types of fluorophores available from Thermo Fisher Scientific (Waltham, MA), such as NovaFluor dyes, which are based on Phiton technology utilizing novel nucleic acid dye structures, Alexa Fluor dyes, nanocrystals such as quantum dots (e.g., Qdot nanocrystals), and polymer dyes such as Super Bright Polymer Dyes or violet / ultraviolet polymer dyes such as Brilliant Ultra Violet™ and Brilliant Violet Polymer Dyes. The detectable label is selected for each of the one or more antibodies to be compatible with the labels selected for the protein and nucleic acid targets being detected.
[0036] In some aspects, the signal generating system includes a target-specific nucleic acid probe and a signal amplification component. In some examples, the signal amplification component comprises a branched nucleic acid (e.g., a pre-amplifier), an amplifier, and a detectably labeled probe (for example, as illustrated in FIG. 1). In further examples, the detectably labeled probe includes one or more fluorophores. Exemplary fluorophores include Alexa Fluor™ dyes (such as Alexa Fluor 488, Alexa Fluor 647, Alexa Fluor 546, Alexa Fluor 750). In other examples, the fluorophore can be selected from xanthene, fluorescein, rhodamine, rhodol, roseamine, carbopyranone, indole, indacene, borapolyazaindacene, furan, benzofuran, cyanine, benzocyanine, benzopyrilium, pyrene, coumarin, styryl, squarine, resorufin, anthraquinone, acridine and benzophenoxazine. Examples of fluorophores suitable for use with the disclosed assays, include, but are not limited to, 6-carboxyfluorescein (FAM), tetrachlorofluorescein (TET), tetramethylrhodamine (TMR), hexachlorofluorescein (HEX), JOE, 6-carboxy-X-rhodamine (ROX), CAL Fluor™, Pulsar™, Quasar™, Texas Red™, Texas Red-X, Cy™3, Cy™5, BODIPY (boron-dipyrromethene), Alexa Fluor dyes (such as Alexa Fluor 488), and Oregon Green. Other examples of fluorophores that can be used in the methods disclosed herein include, but are not limited to: 4- acetamido-4'-isothiocyanatostilbene-2,2'disulfonic acid, acridine and derivatives such as acridine and acridine isothiocyanate, 5 -(2'-aminoethyl)amino-naphthalene-l -sulfonic acid (EDANS), 4-amino-N-[3-vinylsulfonyl)phenyl]-naphthalimide-3,5 disulfonate (Lucifer Yellow VS), N-(4-anilino-l-naphthyl)-maleimide, anthranilamide, Brilliant Yellow, coumarin and derivatives such as coumarin, 7-amino-4-methylcoumarin (AMC, Coumarin 120), 7-amino-4-trifluoromethylcouluarin (Coumaran 151); cyanosine; 4',6-diaminidino-2-phenylindole (DAPI); 5', 5" -dibrom opyrogallol- sulfonephthalein (Bromopyrogallol Red); 7-diethylamino-3-(4'-isothiocyanatophenyl)- 4-methylcoumarin; diethylenetriamine pentaacetate; 4,4'-diisothiocyanatodihydro- stilbene-2,2'-di sulfonic acid; 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid; 5- [dimethyl-amino]naphthalene-l -sulfonyl chloride (DNS, dansyl chloride); 4-(4'- dimethyl-aminophenylazo)benzoic acid (DABCYL); 4- dimethylaminophenylazophenyl-4'-isothiocyanate (DABITC); eosin and derivatives such as eosin and eosin isothiocyanate; erythrosin and derivatives such as erythrosin B and erythrosin isothiocyanate; ethidium; fluorescein and derivatives such as 5- carboxyfluorescein (FAM), 5-(4,6-dichlorotriazin-2-yl)aminofluorescein (DTAF), 2'7'- dimethoxy-4'5'-dichloro-6-carboxyfluorescein (JOE), fluorescein, fluorescein isothiocyanate (FITC), and QFITC (XRITC); fluorescamine; IR144; IR1446; Malachite Green isothiocyanate; 4-methylumbelliferone; ortho cresolphthalein; nitrotyrosine; pararosaniline; Phenol Red; B-phycoerythrin; o-phthaldialdehyde; pyrene and derivatives such as pyrene, pyrene butyrate and succinimidyl 1 -pyrene butyrate;
[0037] Reactive Red 4 (Cibacron® Brilliant Red 3B-A); rhodamine and derivatives such as 6- carboxy-X-rhodamine (ROX), 6-carboxyrhodamine (R6G), lissamine rhodamine B sulfonyl chloride, rhodamine (Rhod), rhodamine B, rhodamine 123, rhodamine X isothiocyanate, sulforhodamine B, sulforhodamine 101 and sulfonyl chloride derivative of sulforhodamine 101 (Texas Red); N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA); tetramethyl rhodamine; tetramethyl rhodamine isothiocyanate (TRITC); riboflavin; rosolic acid and terbium chelate derivatives. The detectable label is selected for each of the one or more target nucleic acids to be compatible with the labels selected for the protein and other nucleic acid targets being detected.
[0038] In particular aspects, detecting the one or more labeled antibodies and detecting the signal generated by the signal generating system utilizes flow cytometry. The flow cytometry instrument utilized is capable of detecting EVs. In some examples, the flow cytometer is capable of detecting particles of about 7 nm to 1 pm in diameter, for example, about 10 nm to 200 nm or about 30-100 nm in diameter. In one example, the flow cytometer is a nanoFCM instrument (NanoFCM Co., Ltd, Nottingham, UK). In other examples, the flow cytometer can include a Bigfoot spectral cell sorter (Invitrogen), Attune NXT and Attune™ CytPix™ Flow Cytometers (Thermo Fisher Scientific), Aurora spectral flow cytometer (Cytek), ZE5 Cell Analyzer (Bio-Rad), Micro PLUS and A50-Micro nanoscale flow cytometers (Apogee), or CytoFLEX (Beckman Coulter).
[0039] In additional aspects, the methods further include one or more washing steps. In some examples, the one or more washing steps are included between contacting the captured EVs with a fixation reagent and contacting the captured EVs with a permeabilization reagent and / or between contacting the captured EVs with a permeabilization reagent and contacting the captured EVs with the one or more nucleic acid detection reagents. In some examples, the wash buffer includes saline, such as phosphate buffered saline. In some examples, the wash buffer includes EV-depleted fetal bovine serum (such as exosome-depleted FBS, Thermo Fisher).
[0040] II. Targets
[0041] The methods provided herein allow the detection of one or more protein targets and one or more nucleic acid targets in EVs. In some examples, the detection of the one or more protein targets and one or more nucleic acid targets is performed in the same assay or workflow. In some examples, the detection of the protein and nucleic acid targets are simultaneous or essentially simultaneous.
[0042] In some aspects, the methods include detection of one or more protein targets (such as 1, 2, 3, 4, or more protein targets). In some examples, the methods include detecting 1-3 protein targets. In some examples, the one or more protein targets are present on the surface of the EV, are internal to the EV, or both.
[0043] In further aspects, the methods include detection of one or more nucleic acid targets (such as 1, 2, 3, 4, or more nucleic acid targets). In some examples, the methods include detecting 1-4 nucleic acid targets. In some examples, the one or more nucleic acid targets are RNA. In particular examples, the one or more nucleic acid targets include coding and / or non-coding RNAs, such as one or more of messenger RNA (mRNA), microRNA (miRNA), ribosomal RNA (rRNA), long non-coding RNA, and small non-coding RNA.
[0044] In some examples, one or more of the nucleic acid targets is mRNA. In other examples, one or more of the nucleic acid targets is a small non-coding RNA, such as a microRNA (miRNA), which are single-stranded RNA molecules that regulate gene expression. miRNAs are generally about 18-25 nucleotides in length. microRNAs typically modulate gene expression (e.g., increase or decrease translation) by promoting cleavage of target mRNAs or by blocking translation of the cellular transcript. miRNAs are processed from primary transcripts known as pri-miRNA to short stem-loop structures called precursor (pre)-miRNA and finally to functional, mature miRNA. Mature miRNA molecules are partially complementary to one or more messenger RNA molecules, and their primary function is to down-regulate gene expression. miRNA sequences are publicly available. For example, miRBase (mirbase.org) includes a searchable database of annotated miRNA sequences. miRNA sequences are also available through other databases known to one of ordinary skill in the art, including the National Center for Biotechnology Information (ncbi.nlm.nih.gov). One of ordinary skill in the art can also identify targets for specific miRNAs utilizing public databases and algorithms, for example at MicroCosm Targets (ebi.ac.uk / enright- srv / microcosm / htdocs / targets / ), TargetScan (targetscan.org), and PicTar (pictar.mdc- berlin.de).
[0045] Additional small (or short) non-coding RNAs include non-coding RNA of about 60 nucleotides or less. In some examples, the small non-coding RNA is small interfering RNA (siRNA), which are about 19-23 nucleotides in length. siRNAs are double-stranded nucleic acid molecules that modulate gene expression through the RNAi pathway. siRNA molecules generally have 2-nucleotide overhangs on each 3 ' end. However, siRNAs can also be blunt ended. Generally, one strand of a siRNA molecule is at least partially complementary to a target nucleic acid, such as a target mRNA. siRNAs are also referred to as “small inhibitory RNAs” or “short inhibitory RNAs.” Additional small non-coding RNAs include Piwi-interacting RNA (piRNA), which are about 25-30 nucleotides in length and bind Piwi proteins. piRNAs are involved in germ cell development, stem cell self-renewal, and retrotransposon silencing. Transcription initiation RNAs (tiRNAs) are about 18 nucleotides in length. They are generally found downstream of transcriptional start sites and are involved in regulating transcription of protein-coding genes by targeting epigenetic silencing complexes. Centromere repeat associated small interacting RNA (crasiRNA) are about 34-42 nucleotides in length and are processed from longer dsRNAs. They are involved in recruitment of heterochromatin and / or centromeric proteins. Another type of small non-coding RNA is telomere-specific small RNA (tel-siRNA), which are about 24 nucleotides in length and are 2'-O-methylated at their 3' end. They are involved in epigenetic regulation. An additional type of small non-coding RNA is Y-RNA (see, e.g., Valkov et al., Adv. Exp. Med. Biol. 1229:327-342, 2020).
[0046] In other examples, one of more of the target nucleic acids is a long non-coding RNA (IncRNA). IncRNAs are transcripts of about 200 nucleotides or more that are not translated into protein. These include long intervening / intergenic noncoding RNAs (lincRNAs), intronic non-coding RNAs and sense and antisense IncRNAs.
[0047] III. Samples
[0048] In further aspects, the sample is a biological specimen containing nucleic acids and proteins, for example, a specimen including EVs. In some examples, the sample is a liquid biopsy specimen. Exemplary samples include blood, plasma, serum, saliva, urine, cerebrospinal fluid, breast milk, cell culture supernatant, or lymphatic fluid. In some examples, the specimen including EVs is from a mammalian source. In other examples, the specimen including EVs is from a non-mammalian source (such as birds, reptiles, amphibians, plants, algae, bacteria, fungi, or insects). In further examples, the sample is an isolated or purified EV preparation. In certain examples, the sample can include engineered EV’s.
[0049] In particular examples, samples are used directly (e.g., fresh or frozen), or can be manipulated prior to use. In some examples, the sample is processed to enrich or isolate EVs, for example, to remove particles that can interfere with the disclosed methods, such as lipoproteins.
[0050] In some examples, the sample is from a subject with a disease or disorder, for example, a subject with cancer, a neurological disorder, a cardiovascular disorder, an infectious disease, a metabolic disorder, or an immunological disorder. The disclosed methods may be utilized to diagnose or prognose a subject, monitor disease progression or therapeutic efficacy, and / or define disease-related biomarker signatures. In certain methods, the EVs can be used as drug delivery vehicles.
[0051] EXAMPLES
[0052] The following examples are provided to illustrate particular features of certain aspects of the disclosure, but the scope of the claims should not be limited to those features exemplified.
[0053] Example 1
[0054] Detection of Protein and RNA in Bead-Bound Extracellular Vesicles
[0055] Sample Preparation: Frozen human plasma was used for all EV experiments. Plasma was isolated from whole blood from San Diego Blood Bank via Cytiva Ficoll- Paque™ PLUS gradient separation, with lx PBS and 10% exosome-depleted FBS. Platelets were then depleted from the plasma sample. All plasma samples were stored as 1 mL aliquots in Eppendorf Protein LoBind® tubes, preserved in 10% DMSO, at -80°C until use. Frozen plasma samples were thawed for 5 minutes in a water bath at room temperature. All buffers were filtered with 0.1 pm pore-size PES membrane prior to use.
[0056] Test Methods: All antibodies and probes used were from Thermo Fisher Scientific (see Table 1) and were used at optimal concentration (5 pL), unless stated otherwise. EVs bound to magnetic beads were stained overnight with antibodies at 4°C, on an end-over-end rotator. The EVs were eluted the following morning, per the manufacturer’s protocol. All samples were handled in Eppendorf Protein LoBind® tubes. DynaMag™-2 magnets were used for all wash steps. EVs were bound to protein-based beads, and stained with CD9 PE overnight at 4°C in the dark on an end-over-end rotator. The bound EVs were then fixed, permeabilized and hybridized with respective target specific probes followed by signal amplification before analysis. 1% Triton-X control samples for all experiments were treated for 45 minutes at 4°C before sample collection on the cytometer.
[0057] Data Analysis: Eluted single EV samples were diluted 1 :4 with 0.1 pm-filtered lx PBS, in polypropylene FACs tubes, and collected on the Bigfoot™ Spectral Cell Sorter for 3 minutes / sample at -150 events / flow rate to mitigate swarming. Samples collected were triggered off PE or APC fluorescence and the 405 nm small particle detector, on log-scale.
[0058] EVs bound to beads were diluted 1 :20 with 0.1 pm-filtered lx PBS, in polypropylene FACs tubes, and collected on the Cytek™ Aurora Spectral Cytometer for 3 minutes / sample on low flow rate to mitigate swarming.
[0059] All data was analyzed using FlowJo® software
[0060] Table 1. Antibodies and mRNA and miRNA probes
[0061] PrimeFlow™ assay was performed to detect miRNA in human peripheral blood mononuclear cells (PBMC). As illustrated in FIGS. 2A-2G, miR-146a was detected in PBMCs, with higher signal in myeloid cells than in lymphocytes. FIG. 3A shows that Virocheck beads (Invitrogen) were used to locate and gate single EVs with doublet exclusion, after elution from magnetic beads. Virocheck beads are used to determine size resolution capability of a flow cytometer. CD9, CD63, and CD81 were detected on single EVs using Bigfoot™ spectral cell sorter (FIG. 3B). As CD9+ EVs were found to be the prevalent population, titrations of CD9 and its isotype control (mlgGl) were used to determine application-dependent optimal concentrations for CD9. The plasma- derived EVs were stained overnight at 2x, lx, 0.5x and 0.25x at the optimal concentration. The stained EVs were washed and eluted the next morning, and detected on the Bigfoot™ spectral cell sorter. No increase in CD9 signal was observed at 2x, and slight decrease in CD9 signal was observed at 0.5x and 0.25x. Thus, optimal concentration of CD9 antibody performs comparably for both cells and EVs alike.
[0062] FIGS 4A-4B shows the FSC / SCC and single bead-EV gating strategy of EVs bound to magnetic beads. Detection of mRNA and miRNA in bead-bound EVs was performed using Cytek™ Aurora cytometer. miR-146 and GAPDH were detected in membrane-bound EVs (CD9+), while RPL13a, was not detected (FIGS. 4E). Appropriate control samples included (FIG. 4B) unstained EVs bound to magnetic beads, (FIG. 4C) magnetic beads (no EVs bound) plus mRNA or miRNA probes, and (FIG. 4D) EV-bound beads with mRNA or miRNA probe.
[0063] Example 2 Detection of Protein and RNA in Single Extracellular Vesicles
[0064] This example describes an exemplary protocol for detecting protein and RNA targets in single EVs. The protocol can include all or a portion of the listed steps, and certain steps of the protocol can be performed in a different order than listed. The instant protocol utilizes components from the Invitrogen™ CELLection™ Epithelial Enrich Dynabeads™ product (Cat. No. 16203) from Thermo Fisher Scientific (Waltham, VIA). 1. Add ~10 pg primary antibody (e.g., CD9-PE) to ImL plasma-derived EV serum and mix (titrate the antibody amount as needed).
[0065] 2. Incubate overnight at 2-8°C, on an end-over-end rotator.
[0066] 3. Vortex Dynabeads for >30 seconds to resuspend the beads.
[0067] 4. Transfer 25 pL Dynabeads magnetic beads to a LoBind® Eppendorf tube.
[0068] 5. Add the same volume of Buffer 1, or at least ImL, and resuspend.
[0069] 6. Place tube in an Invitrogen DynaMag Magnet (Thermo Fisher Scientific) for 1 minute. Discard the supernatant.
[0070] 7. Remove tube from DynaMag and resuspend the washed magnetic beads in the same volume as step 4.
[0071] 8. Add ImL of overnight stained plasma EV to the washed magnetic beads.
[0072] 9. Add ImL of Buffer 2 (refer to protocol set forth in Invitrogen™ CELLection™ Epithelial Enrich Dynabeads™ product to limit trapping of unbound EVs.
[0073] 10. Incubate for 20 minutes at 2-8°C with gentle tilting and rotation.
[0074] 11. Place tube in DynaMag for 2 minutes. Remove the supernatant.
[0075] 12. Remove tube from DynaMag and add ImL Buffer 1, pipet 2-3x.
[0076] 13. Return tube to DynaMag for 2 minutes. Remove supernatant.
[0077] Antibody staining, sample fixation and sample permeabilization.
[0078] 14. Prepare PrimeFlow microRNA pretreatment buffer, and add 200 pL to sample.
[0079] 15. Incubate 15 minutes in the dark at room temperature.
[0080] 16. Place on DynaMag for 2 minutes, and remove supernatant.
[0081] 17. Remove from DynaMag. Wash sample with 200 pL filtered PBS.
[0082] 18. Place sample back on DynaMag for 2 minutes, and remove supernatant.
[0083] 19. Prepare Fixation Buffer 1 by mixing together equal parts PrimeFlow RNA Fixation Buffer 1 A and PrimeFlow RNA Fixation Buffer IB. Invert gently to mix.
[0084] 20. Add 200 pL Fixation Buffer 1 to sample, pipet to mix.
[0085] 21. Incubate for 30 minutes at 2-8°C.
[0086] 22. Place on DynaMag for 2 minutes. Remove supernatant.
[0087] 23. Prepare RNA permeabilization buffer with RNase Inhibitors. 24. Add 200 pL RNA permeabilization buffer to sample.
[0088] 25. Incubate 2-3 minutes at 2-8°C, then place on DynaMag for 2 minutes. Remove supernatant.
[0089] 26. Repeat steps 26-27 for total of 2x permeabilizations.
[0090] 27. Prepare RNA Wash Buffer.
[0091] 28. Wash sample with 200 pL wash buffer. Incubate for 2 minutes at room temperature.
[0092] 29. Place sample on DynaMag for 2 minutes. Remove supernatant.
[0093] 30. Repeat steps 30-31 for total of 2x washes with RNA wash buffer.
[0094] 31. (Option to store sample overnight at this step; store and cover sample in 100 pL wash buffer with RNase Inhibitor, at 2-8°C.)
[0095] Target probe hybridization.
[0096] 32. Thaw Target Probe Sets (20X) at room temperature.
[0097] 33. Pre-warm RNA wash buffer to room temperature before use.
[0098] 34. Pre-warm PrimeFlow RNA Target Probe Diluent to 40°C.
[0099] 35. Dilute Target Probes 1 / 20 in PrimeFlow™ RNA Target Probe Diluent. Mix thoroughly by pipetting up and down.
[0100] 36. Add 100 pL RNA wash buffer to sample, and then add 100 pL Target probe to sample.
[0101] 37. Cover sample, and incubate for 2 hours at 40°C.
[0102] 38. Remove sample from incubator and place on DynaMag for 2 minutes. Remove supernatant.
[0103] 39. Add 200 pL RNA wash buffer.
[0104] 40. Place on DynaMag for 2 minutes. Remove supernatant.
[0105] 41. Repeat steps 42-43 for a total of 2 washes.
[0106] Signal amplification.
[0107] 42. Pre-warm PrimeFlow RNA PreAmp Mix, PrimeFlow™ RNA Amp Mix, and PrimeFlow RNA Label Probe Diluent to 40°C.
[0108] 43. Thaw PrimeFlow RNA Label Probes (100X) on ice in the dark. 44. Add 100 pL of PrimeFlow RNA PreAmp Mix directly into the sample, and pipet to mix.
[0109] 45. Cover and incubate sample for 1.5 hours at 40°C.
[0110] 46. Remove sample from incubator and place on DynaMag for 2 minutes. Remove supernatant.
[0111] 47. Add 200 pL RNA wash buffer.
[0112] 48. Place on DynaMag for 2 minutes and remove supernatant.
[0113] 49. Repeat steps 51-52 for total of 2 washes.
[0114] 50. Add 100 pL of RNA Wash Buffer to sample.
[0115] 51. Then add 100 pL of PrimeFlow RNA Amp Mix directly into sample, and pipet to mix.
[0116] 52. Incubate plate with the lid on for 1.5 hours at 40°C.
[0117] 53. Remove sample from incubator and place on DynaMag for 2 minutes. Remove supernatant.
[0118] 54. Add 200 pL RNA wash buffer to sample.
[0119] 55. Place on DynaMag for 2 minutes, and remove supernatant.
[0120] 56. Repeat steps 58-59 for total of 2 washes.
[0121] 57. Prepare label probes by diluting PrimeFlow RNA Label Probes (100X) 1 / 100 in PrimeFlow RNA Label Probe Diluent.
[0122] 58. Add 100 pL of RNA Wash Buffer to sample, then add 100 pL of diluted RNA Label Probes directly into the suspension, and pipet to mix.
[0123] 59. Cover and incubate sample for 1 hour at 40°C.
[0124] 60. Remove sample from incubator and place on DynaMag for 2 minutes. Remove supernatant.
[0125] 61. Add 200 pL RNA wash buffer to sample.
[0126] 62. Place on DynaMag for 2 minutes. Remove supernatant.
[0127] 63. Repeat steps 65-66 for total of 2 washes.
[0128] Elution of EV sample from CELLection beads.
[0129] 64. Divide EV sample into 3 groups with equal volume in each.
[0130] 65. GROUP 1 : 66. Prepare EV-Flow Stain buffer (EV-FSB); lx filtered PBS with 10% exosome- depleted fetal bovine serum.
[0131] 67. Wash sample 1 with 200 pL EV-FSB.
[0132] 68. Place on DynaMag for 2 minutes, remove supernatant.
[0133] 69. Repeat steps 70-71 for total of 3 washes,
[0134] 70. Go to step 77.
[0135] 71. GROUP 2:
[0136] 72. Perform steps 70-71 for total of 3 washes on sample 2.
[0137] 73. Add 200 pL EV-FSB to sample 2, and cover and store overnight at 2-8°C in the dark.
[0138] 74. Go to step 77.
[0139] 75. GROUP 3:
[0140] 76. Go directly to step 77.
[0141] 77. Place sample on DynaMag for 2 minutes, and remove supernatant.
[0142] 78. Remove sample from DynaMag.
[0143] 79. Add 1 mb Buffer 1 (CELLect protocol) to sample, and pipet 2-3 times (or vortex 2-3 seconds).
[0144] 80. Place sample on DynaMag for 2 minutes, and remove supernatant.
[0145] 81. Repeat steps 79-80 for total of 2 washes to obtain high purity of isolated EVs.
[0146] 82. Resuspend the bead-bound EVs in 200pL pre-heated (37°C) Buffer 3 (from CELLect protocol).
[0147] 83. Add 4 pL reconstituted Release Buffer (DNase I).
[0148] 84. Incubate for 15 minutes at room temperature with gentle tilting and rotation.
[0149] 85. Pipet thoroughly with 100-200 pL pipette 5-10 times to maximize EV release. Avoid foaming.
[0150] 86. Before transferring the released EVs to a new tube in the next step, pre-coat the new tubes with Buffer 3 for 5 minutes.
[0151] 87. Place in DynaMag for 2 minutes, and transfer the supernatant with released EVs into the pre-coated tubes.
[0152] 88. Resuspend the bead fraction in 200 pL Buffer 3. 89. Repeat step 87 once to collect residual EVs.
[0153] 90. Run eluted EV sample on flow cytometer.
[0154] It will be apparent that the precise details of the methods or compositions described may be varied or modified without departing from the spirit of the described aspects of the disclosure. We claim all such modifications and variations that fall within the scope and spirit of the claims below.
Claims
CLAIMSWe claim:
1. A method of detecting one or more protein and one or more nucleic acid targets in extracellular vesicles (EVs) in a sample, the method comprising: capturing EVs in the sample on a solid surface or bead to produce captured EVs; labeling the captured EVs with one or more detectably labeled antibodies; contacting the captured EVs with a fixation reagent; contacting the captured EVs with a permeabilization reagent; contacting the captured EVs with one or more nucleic acid detection reagents comprising a signal generating system to provide treated EVs; and detecting the one or more labeled antibodies and detecting a signal generated by the signal generating system, thereby detecting the one or more protein and one or more nucleic acid targets in the treated EVs.
2. A method of detecting one or more protein and one or more nucleic acid targets in extracellular vesicles (EVs) in a sample, the method comprising: labeling EVs in the sample with one or more detectably labeled antibodies; capturing the labeled EVs on a solid surface or bead to produce captured EVs; contacting the captured EVs with a fixation reagent; contacting the captured EVs with a permeabilization reagent; contacting the captured EVs with one or more nucleic acid detection reagents comprising a signal generating system to provide treated EVs; and detecting the one or more labeled antibodies and detecting a signal generated by the signal generating system, thereby detecting the one or more protein and one or more nucleic acid targets in the treated EVs.
3. A method of detecting one or more protein and one or more nucleic acid targets in extracellular vesicles (EVs) in a sample, the method comprising:capturing EVs in the sample on a first solid surface or bead to produce capturedEVs; releasing the captured EVs from the solid surface or bead to produce released EVs; labeling the released EVs with one or more detectably labeled antibodies; contacting the released EVs with a fixation reagent; contacting the released EVs with a permeabilization reagent; contacting the released EVs with one or more nucleic acid detection reagents comprising a signal generating system to provide treated EVs; capturing the treated EVs on a second solid surface or bead to produce captured, treated EVs; and detecting the one or more labeled antibodies and detecting a signal generated by the signal generating system, thereby detecting the one or more protein and one or more nucleic acid targets in the EVs.
4. The method of claim 1, claim 2, or claim 3, wherein the captured EVs are reversibly bound to the solid surface or bead.
5. The method of claim 4, wherein the reversible binding comprises a cleavable linker or a nano DNA structure.
6. The method of claim 5, wherein the cleavable linker is a DNA linker, a chemically-cleavable linker, or an enzyme cleavage site.
7. The method of claim 6, wherein the DNA linker is cleaved by DNase I.
8. The method of any one of claims 1 to 7, wherein the solid surface or bead comprises magnetic beads.
9. The method of any one of claims 1 to 8, further comprising releasing the reversibly bound captured EVs from the solid surface or bead prior to detecting the one or more labeled antibodies and detecting the signal generated by the signal generating system.
10. The method of any one of claims 1 to 9, wherein the signal generating system comprises a target-specific nucleic acid probe and a signal amplification component.
11. The method of claim 10, wherein the signal amplification component comprises a branched nucleic acid (pre-amplifier), an amplifier, and a detectably labeled probe.
12. The method of claim 11, wherein the detectably labeled probe comprises one or more fluorophores.
13. The method of any one of claims 1 to 12, wherein detecting the one or more labeled antibodies and detecting the signal generated by the signal generating system utilizes flow cytometry.
14. The method of any one of claims 1 to 12, further comprising one or more washing steps.
15. The method of claim 14, wherein one or more washing steps are between contacting the captured EVs with a fixation reagent and contacting the captured EVs with a permeabilization reagent and / or between contacting the captured EVs with a permeabilization reagent and contacting the captured EVs with the one or more nucleic acid detection reagents.
16. The method of claim 14, wherein the washing step comprises a wash buffer comprising EV-depleted fetal bovine serum.
17. The method of any one of claims 1 to 16, wherein the nucleic acids compriseRNA.
18. The method of claim 17, wherein the RNA comprises one or more of mRNA, miRNA, long non-coding RNA, and small non-coding RNA.
19. The method of any one of claims 1 to 18, wherein the sample comprises a biological specimen.
20. The method of claim 19, wherein the biological specimen is a liquid biopsy specimen or cell culture supernatant.
21. The method of any one of claims 1 to 20, wherein the sample is from a subject with a disease or disorder.
22. The method of claim 21, wherein the disease or disorder is cancer, a neurological disorder, a cardiovascular disorder, an infectious disease, a metabolic disorder, or an immunological disorder.
Citation Information
Patent Citations
Systems and methods for vesicle cargo labeling and detection
US20220113313A1
Methods for isolating surface marker displaying agents
WO2019222708A2
